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Abstract
Background: Idiopathic pulmonary fibrosis (IPF) and chronic obstructive pulmonary disease (COPD) are disorders
of the lung parenchyma. They share the common denominators of a progressive nature and poor prognosis. The
goal was to use non-biased proteomics to discover new markers for these diseases.
Methods: Proteomics of fibrotic vs. control lung tissue suggested decreased levels of several spots in the lung
specimens of IPF patients, which were identified as Hemoglobin (Hb) a and b monomers and Hba complexes. The
Hba and b monomers and complexes were investigated in more detail in normal lung and lung specimens of
patients with IPF and COPD by immunohistochemistry, morphometry and mass spectrometry (MS).
Results: Both Hb monomers, in normal lung, were expressed especially in the alveolar epithelium. Levels of Hba
and b monomers and complexes were reduced/lost in IPF but not in the COPD lungs when compared to control
lung. MS-analyses revealed Hba modification at cysteine105 (Cysa105), preventing formation of the Hba
complexes in the IPF lungs. Hba and Hbb were expressed as complexes and monomers in the lung tissues, but
were secreted into the bronchoalveolar lavage fluid and/or induced sputum supernatants as complexes
corresponding to the molecular weight of the Hb tetramer.
Conclusions: The abundant expression of the oxygen carrier molecule Hb in the normal lung epithelium and its
decline in IPF lung are new findings. The loss of Hb complex formation in IPF warrants further studies and may be
considered as a disease-specific modification.
Background
Idiopathic pulmonary fibrosis (IPF) (histopathology of
usual interstitial pneumonia, UIP) is classified as one of
the idiopathic interstitial pneumonias, representing an
entity with unknown etiology, aggressive fibrogenesis
and a very poor prognosis [1,2]. IPF is considered pri-
marily as a disease associated with epithelial/fibroblastic
pathology [3,4]. Chronic obstructive pulmonary disease
( C O P D )i sas l o w l yp r o g r e s s i v eb u tv e r yc o m m o nl u n g
disease, with most of the cases being related to smoking.
COPD involves not only airway inflammation/obstruc-
tion but also varying degrees of parenchymal lung
damage i.e. emphysema combined with small airway
fibrosis and the occurrence of patchy fibrotic lesions in
the lung parenchyma. Despite recent advances in our
understanding of the pathogenesis of these diseases, the
precise molecular mechanisms leading to their progres-
sion remain unclear, and there is no effective therapeu-
tic strategy for either of these disorders.
Both IPF and COPD have been shown to be asso-
ciated with oxidative/nitrosative stress [5-7]. The ele-
vated oxidant burden in turn triggers the activation of
growth factors and metalloproteases and evokes an
imbalance in the acetylases/deacetylases and disruptions
of the transcription of several inflammatory genes in the
lung [8,9]. Due to several overlapping features between
chronic airway and parenchymal lung diseases, there is
an urgent need to understand better disease specific
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response to treatment.
The present study was undertaken to use non-biased
proteomics to clarify the mechanisms related to these
two lung diseases i.e. IPF and COPD, and to identify
disease specific markers.O u rr e c e n tp r o t e o m i c
approaches at pH 4-7 have revealed altered expression
of several spots in the lung specimens of COPD and
IPF, which were identified to represent surfactant pro-
tein A [10] and various RAGE (receptor for advanced
glycation endproducts) isoforms [11]. Further screening
at pH 6-11 revealed a loss of a third group of proteins
in the lung specimens of the patients with IPF; corre-
sponding changes could not be found in the COPD
lung. These spots were identified by MS and found to
represent Hemoglobin (Hb) a and b monomers and
Hba complexes. The wide spectrum of Hb functions
extends from oxygen (O2)b i n d i n ga n dt r a n s p o r t ,n i t r i c
oxide (NO) metabolism, blood pressure regulation, to
protection against oxidative and nitrosative stress
[12-14]. The distribution, expression or significance of
Hb and its subchains have not been investigated in lung
diseases. In this study, Hba and Hbb monomers and
complexes were investigated in more detail in normal
lung and lung specimens of patients with IPF and
COPD by Western blot, immunohistochemistry, mor-
phometry and mass spectrometry (MS). In addition, Hb
(a, b) levels in bronchoalveolar lavage (BAL) and
induced sputum samples were investigated to elucidate
whether Hb would be detectable in these samples and
could possibly be used in the evaluation of these
diseases.
Methods
Study subjects
Tissue samples were collected by lung surgery from
patients treated in Helsinki University Central Hospital.
All control tissues were obtained from lung surgery
from hamartomas or from the surgery of local tumors
(controls), or from lung transplantations (COPD Stage
IV and IPF lung). Bronchoalveolar lavage fluid (BALF)
and sputum samples were collected from patients of the
Division of Pulmonary Medicine, Helsinki University
Central Hospital or healthy volunteers. Each IPF case
was confirmed and re-evaluated to represent UIP histo-
pathology by an experienced pathologist. COPD was
defined according to GOLD criteria (FEV1 < 80% of
predicted, FEV1/FVC < 70% and bronchodilatation
effect < 12%) [15,16]. Five to 10 mg oral predonisolone
and/or inhaled corticosteroids had been included in the
regular therapy of all IPF patients and Stage IV (very
severe) COPD, none of the other subjects were receiving
regular corticosteroid therapy. The Ethics Committee of
the Helsinki University Central Hospital approved the
study and all patients received written information and
gave their permission to use the samples. Characteristics
of the patients are shown in Tables 1, 2 and 3.
Bronchoalveolar lavage fluid (BALF)
Bronchoalveolar lavage was performed under local
anesthesia to a representative lung segment with 200 ml
of sterile 0.9% saline according to the standard proce-
dure as described [17]. The fluid was centrifuged at 400
×g for 10 min at +4°C to separate the cells from the
supernatant. The supernatants were divided into smaller
aliquots and stored at -80°C for further experiments.
The subjects represented patients who had been investi-
gated for prolonged cough, but whose lung function,
high resolution computed tomography (HRCT) and
BAL cell profiles were normal and who recovered
Table 1 Characteristics of the controls, IPF and COPD
patients in the 2-DE analyses of the lung homogenates
Control COPD
Stage IV
IPF
Patients, n 4 4 4
Age, yr 59 ± 7 58 ± 4 54 ± 5
Sex, M/F 3/1 1/3 3/1
Pack years, yr < 12 * 32 ± 2*** 15**
FEV1 (%) 89 ± 10 12 ± 2*** 38 ± 3***
FVC (%) 77 ± 1 31 ± 4 *** 35 ± 3***
Data are presented as mean ± SEM.
* Three of the controls were never smokers and one of the controls had
smoked 10 to 12 years but stopped smoking at least 2 years before the study.
** Three of the IPF patients were never smokers and one of the IPF patients
had smoked but stopped smoking 30 years before the surgery.
*** p < 0.05 versus control subjects. All patients with COPD stage IV had been
smoked but stopped smoking at least 2 years before the study.
Table 2 Characteristics of the control, COPD and IPF
patients in the Hemoglobin alpha and beta Western blot
analyses of the lung homogenates
Control Smoker COPD
Stage IV
IPF
Patients, n 7 7 7 7
Age, yr 65 ± 3 62 ± 3 58 ± 2 56 ± 3
Sex, M/F 4/3 6/1 4/3 5/2
Pack years, yr 7 ± 5 * 21 ± 6 31 ± 5** 6 ± 5 ***
FEV1 (%) 100 ± 6 88 ± 3 22 ± 5
# 47 ± 6
#
FVC (%) 102 ± 6 87 ± 4 47 ± 8
# 43 ± 5
#
Data are presented as mean ± SEM.
* Four of the controls were never smokers and two of the controls had
smoked 10-15 years but stopped smoking at least 2 years before the study;
one of the controls had smoked 30 years but stopped smoking one year
before the study.
** All the patients were smokers, but had stopped smoking at least 2 years
before the study. *** Five of the IPF patients were never smokers; two had
smoked for over 5 years but stopped smoking at least two years before the
study.
# p < 0.05 versus control subjects and healthy smokers.
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disease. Characteristics of the patients are shown in
Table 4.
Induced sputum
Sputum was induced by inhalation of hypertonic saline
as recommended by the European
Respiratory Society Task Force and processed as
described [18,19]. Induced sputum supernatants for
Western blot were collected and immediately transferred
to -80°C. The specimens were obtained from healthy
nonsmokers whose lung function values were normal.
Characteristics of these subjects are shown in Table 4.
Two-Dimensional Gel Electrophoresis (2-DE) and Protein
Identification
2-DE analyses were performed as described earlier
[10,11]. Frozen lung tissue samples were powdered and
further purified by acetone precipitation. The protein
extract was resuspended in urea buffer (6 M urea, 2 M
thiourea, 2% [w/v] CHAPS, 0.15% [w/v] DTT, 0.5% [v/v]
carrier ampholytes 3-10, Complete Mini protease inhibi-
tor cocktail [Roche]), incubated for 10 minutes in an
ultrasonic bath, and centrifuged. Protein aliquots (100
μg) were stored at -20°C. In the alkylation experiment,
the protein extract in alkylation buffer containing 6 M
urea, 2% [w/v] CHAPS, 65 mM DTT and Complete
Mini protease inhibitor cocktail was incubated for 15
min at RT with 130 mM iodoacetamide. The protein
separation for each sample (control lung, IPF and Stage
IV COPD) was done in triplicate. IPG, strips (pH 6-11,
18 cm, GE Healthcare) were rehydrated in 350 μlu r e a
buffer overnight. Prior to application into sample cups
a tt h ea n o d i ce n do ft h eI P G ,t h ep r o t e i ns o l u t i o nw a s
adjusted with urea buffer to a final volume of 100 μl.
Isoelectric focusing (IEF) was carried out with the Mul-
tiphor II system (GE Healthcare) under paraffin oil for
85 kVh. SDS-PAGE was performed overnight in polya-
crylamide gels (12.5% T, 2.6% C) with the Ettan DALT
II system (GE Healthcare) at 1-2 W per gel and 12°C.
The total protein in the gel was visualized by silver
staining. The protein pattern was analyzed with the 2-D
PAGE image analysis software Melanie 3.0 (GeneBio).
The exact positions (isoelectric point [pI], molecular
mass) of the spots were determined from the reference
2-D gel of human lung (pH 6-11) with the identified
marker proteins. The expected spot position was calcu-
lated with the Compute pI/Mw tool (http://au.expasy.
org/tools/pi_tool.html).
In the protein identification, excised spots were
digested as described [11]. Peptide masses were mea-
sured with a VOYAGER-DE™ STR [11] and proteins
identified by full database search (Aldente database ver-
sion 11/02/2008 (http://ca.expasy.org/tools/aldente/)
according to the following parameters (20 ppm; 1
missed cut; [M+H]; +CAM; +MSO). Further informa-
tion about the proteins was obtained from the Swiss-
Prot/TrEMBL database (http://au.expasy.org/sprot/) and
NCBI database (http://www.ncbi.nlm.nih.gov/).
Western Blot Analysis
Western blot analyses of lung tissue homogenates were
performed as described [20-22]. Tissue samples were
homogenized in PBS, and 50 μgo fp r o t e i nw a su s e d
under standard i.e. reducing or non-reducing conditions
[23]. Membranes were probed with goat anti-Hemoglo-
bin alpha (Hba) antibody (H80: sc-21005, Santa Cruz
Biotechnology, Inc. Santa Cruz, CA) or mouse anti-
Hemoglobin beta (Hbb) antibody (M02, Abnova, Taipei,
Taiwan), followed by secondary antibody treatments.
Since the expressions of housekeeping proteins (e.g. b-
actin but possibly also others) vary in airway and
Table 3 Characteristics of the controls, COPD and IPF
patients in the immunohistochemical analyses of the
lung
Control COPD
Stage IV
IPF
Patients, n 6 7 7
Age, yr 64 ± 3 60 ± 2 61 ± 3
Sex, M/F 5/1 4/3 7/0
Pack years, yr 10 ± 7 * 35 ± 5** 15 ± 9 ***
FEV1 (%) 105 ± 5 40 ± 9 **** 60 ± 8****
FVC (%) 104 ± 6 59 ± 6**** 57 ± 7****
Data are presented as mean ± SEM.
* Two of the controls were never smokers and four of the controls had
smoked 10-30 years but stopped smoking at least 2 years before study.
** The patients were ex-smokers, but had stopped smoking at least 2 years
before the study.
*** Three of the IPF patients were never smokers, four had smoked 15-45
years but stopped smoking at least two years before the study.
**** p < 0.05 versus control subjects.
Table 4 Characteristics of the control subjects in the
Hemoglobin Western blot analyses from the BAL fluid
and sputum supernatant
Control (Prolonged
cough)
BALF *
Control (Non-
smokers)
Sputum
n6 7
Age, yr 43 ± 9 50 ± 5
Sex, M/F 2/4 6/1
Smoking/non-
smoking
6/1 ** 0/7
FEV1 3.5 ± 0.5 4.1 ± 0.25
FVC 4.3 ± 0.6 5 ± 0.4
Data are presented as mean ± SEM.
* Subjects with prolonged cough without any interstitial or alveolar
abnormalities by high-resolution computed tomography (HRCT) and with a
normal cell profile in the BALF.
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equal loading was standardized against Ponceau S stain-
ing of the membranes (Sigma Aldrich, St. Louis, MO)
[24-26]. Quantitative analysis of the Western blot bands
as well as the calculation of the corresponding molecu-
lar masses was done with Image J 7.0 software (National
Institutes of Health, Bethesda, MD).
Immunohistochemistry and morphometry
Four mm thick paraffin-embedded tissue sections were
deparaffinized in xylene and rehydrated in graded alco-
hol. NovoLink polymer detection system (RE7150-CE,
Novocastra Laboratories ltd, Newcastle Upon Tyne, UK)
was used for immunostaining according to the manufac-
turer’s instructions. In order to determine the specificity
of the staining series, negative control sections were
treated with mouse isotype control (Zymed Laboratories,
San Francisco, CA, USA) or PBS. Detailed localization of
the expression was further investigated using a large
magnification (900×). Digital morphometry of the
stained tissue sections was conducted as described [27].
Two or three representative images from the lung par-
enchyma of each stained section were taken with an
Olympus U-CMAD3 camera (Olympus Corporation,
Japan) and QuickPHOTO CAMERA 2.1 software (Pro-
micra, Prague, Czech Republic). The areas of positively
vs negatively stained interstitium or alveolar epithelium
were measured with Image-Pro Plus 6.1. software
(Media Cybernetics, UK).
Oxidative/Nitrosative Stress
Nitrotyrosine was used as a marker for oxidative/nitro-
sative stress because it reflects both superoxide and
nitric oxide-mediated reactio n si nt h ec e l l s[ 2 8 ] .N i t r o -
tyrosine distribution and expression in the lung sections
of control, IPF and COPD lung were assessed by immu-
nohistochemistry, as described [22,29]. Detection of
nitrotyrosine was performed with a rabbit anti-nitrotyro-
sine antibody (06-284, Upstate).
Statistical Analysis
Data are presented as mean ± SEM. SPSS for Windows
(Chicago, IL) was used for statistical analysis and the
significance of the associations between two and more
than two variables was assessed with Mann-Whitney U
and Kruskal Wallis test, respectively. Data was calcu-
l a t e da sm e a nf r o ma tl e a s tt w oc o n c u r r e n ts a m p l e so f
several tissue sections of IPF and control; p ≤ 0.05 was
considered statistically significant.
Results
Loss of Hba in the IPF but not in the COPD lungs
Homogenates from control (n = 4) and IPF (n = 4) lung
tissues were separated by 2-DE at pH6-11 to search for
IPF -specific markers. Two highly abundant “spot trains”
at 15 kDa and two spots at a higher molecular mass in
the 2-D gels of all control lungs could be detected,
w h i c hw e r ea b s e n to rc o n s i d e r a b l yr e d u c e di nt h eI P F
lungs (Figure 1). The comparison with COPD (Stage IV,
n = 4), indicated that these alterations were specific for
IPF i.e. no evidence for changes in these spots could be
seen in the COPD lungs. MS analyses revealed that the
“spot trains” represented Hba and Hbb whereas Hba
was also identified in the other spots. The position of
both “spot trains” in the 2-D gel and the theoretical
molecular masses of Hba (15 kDa) and Hbb (16 kDa)
were evidence that both represented monomers. Inter-
estingly the larger molecular masses of spot 1 (27 kDa)
and 2 (26 kDa) indicated the presence of Hba com-
plexes. Since exclusively Hba was detected in these
complexes, they are likely to represent homodimers. No
corresponding changes in the Hbb complexes could be
seen due to a major overlapping of the spots, which is
why it was difficult to characterize their possible
composition.
Decline of Hb complexes and monomers in the IPF but
not in the COPD lungs
The Hba and Hbb levels were investigated next by
Western blot using control lung (control; n = 7), IPF
lungs (n = 7), and lung specimens from smokers with-
o u tC O P D( s m o k e r s ;n=7 )a n dC O P D( n=7 ) .S i n c e
Hb complexes, detected by 2-DE, are known to be
formed through disulfide bonds [30], Hba and Hbb
expression levels were evaluated in two ways i.e. redu-
cing and non-reducing Western blot techniques. Wes-
tern blot analyses confirmed the presence of the
monomers and complexes of Hba and Hbb in the
lung with corresponding molecular weights as in the
2DE. The results on the Hb complexes were very simi-
lar in the standard (Figure 2) and non-reducing Wes-
tern blot (not shown) i.e .t h ep r e s e n c eo ft h eH b a
complexes was completely missing or very low in the
IPF lung. Also the levels of Hba monomer were
higher in the control than in the IPF lungs (1.6 fold)
in the standard Western blot. In addition, the levels of
Hbb complexes were higher in the standard and non-
reducing Western blots (4.6 and 5.1 fold) and the
levels of Hbb monomer higher (3.2 fold) in the non-
reducing Western blots in the control than in the IPF
lungs. The expression levels of Hba,H b b or their
complexes did not differ significantly in the lungs of
the controls, smokers or patients with COPD except
for the assays done under reducing conditions for
Hbb i.e. the level of Hbb monomer was higher (2.3
f o l d )i nt h ec o n t r o lt h a ni nt h eC O P Dl u n g s .T h e s e
results in standard i.e. reducing Western blot condi-
tions, are shown in Figure 2.
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immunoreactivity in the IPF and COPD lung
The distribution of Hba and Hbb in the lung tissue was
next investigated in control, IPF and COPD lung. In
control and COPD lungs, Hba and Hbb could be clearly
detected in the alveolar epithelium with some positivity
of Hba being found also in the bronchiolar/bronchial
epithelium and macrophages (Figure 3A, 3B, high mag-
nification). Both Hba and Hbb immunoreactivities were
low or absent in the alveolar regions, interstitium and
fibroblast foci in the IPF lung. Morphometrical analysis,
which was conducted by excluding blood vessels and
macrophages (since they contain erythrocytes and Hb),
shows the sum of positive bronchiolar/alveolar epithe-
lium and interstitium; Epi+Int) (Figure 3C). In addition,
the Hba and Hbb positive areas in bronchiolar/alveolar
epithelium were evaluated by excluding blood vessels,
macrophages and interstitium (Epi) (Figure 3D). Next,
t h ep o s i t i v ea r e ao fH b a and Hbb was calculated by
using morphometry. As shown in Figure 3E and 3F, the
Hba positive areas (Epi+Int and Epi) between the con-
t r o l ,C O P Da n dI P Fg r o u p sd i ffered significantly (Krus-
kal Wallis test; p =0 . 0 0 7 )w h i l et h eH b b positive areas
(Epi+Int and Epi) did not (Figure 3G, 3H).
Prevention of Hba complex formation by cysteine 105
modification in the IPF lung
I nt h eI P Fl u n g s ,o n l yam o d e s tr e d u c t i o no ft h eH b a
monomer level was observed whereas the Hba complex
was absent (Figures 1, 2). This hinted that an additional
mechanism might be effecting the complex formation. It
has been shown that Hb complexes, detected by 2-DE of
purified human globin chains, are formed through disul-
fide bonds [30]. Hba contains only one cysteine at posi-
tion 105 (Cysa105) likely to be the site responsible for
complex formation. In agreement, MS analyses revealed
that the peptide 3024.6338 containing Cysa105 was pre-
sent in the major Hba spots at 15 kDa but not in the Hba
complexes (Figure 4A, 4B). Therefore the possibility of
complex formation through this cysteine was investigated
in more detail. Alkylation prior to separation abolished the
presence of Hba at the higher molecular mass, indicating
that Cysa105 was indeed involved in the complex forma-
tion (Figure 4C). Overall, the reduced levels of the Hba
complexes in the IPF lungs point to the presence of a
modified thiol group at Cysa105 preventing the complex
formation. It is very likely that the oxidative stress in the
IPF lungs results in the redox regulated modification at
Cysa105, e.g. S-glutathiolation, S-nitrosylation or
Figure 1 Two-dimensional gel electrophoresis (2-DE) reveals alterations of Hba and b monomers and Hba complexes in IPF lungs. (A)
A representative 2-D gel for control lung is shown on the left. The enlarged gel positions (B) represent Hba and b monomers and Hba
complexes (spots 1 and 2) in human control (n = 4), IPF (n = 4) and COPD (Stage IV, n = 4) lung tissue. Lung homogenates were separated by
2-DE (pH6-11) and the protein pattern visualized by silver staining. For patient characteristics see Table 1.
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Page 5 of 13formation of sulfonic acid. Moreover, it is possible that
thiol groups in both Hb subunits may be nitrosylated or
nitrated in vivo, since corresponding findings have been
documented to occur also with Hbb [31,32].
Occurrence of Oxidative/Nitrosative Stress in the IPF and
COPD lung
Due to the disturbance of the Hba complex formation,
most likely via nitrosylation or nitration, only in IPF but
not in COPD lung, it was decided to investigate whether
these two diseases, IPF and COPD, display any major
differences in nitrotyrosine expression in general. Our
earlier studies have revealed that there is remarkable
nitrotyrosine positivity, especially in the fibrotic lung
[22,29], while another study from our laboratory showed
relatively weak nitrotyrosine expression in the COPD
lung parenchyma [33]. This comparison was conducted
by staining both the IPF and COPD lung tissues with
the same techniques at the same time and by analyzing
the positivity in a semiquantitative manner by Western
Figure 2 Relative intensities of (A) Hba complex and (B) monomer and (C) Hbb complex and (D) monomer in control (n = 7), smoker
(n = 7), COPD (n = 7) and IPF lungs (n = 7) determined by standard i.e. reducing Western blot analysis. Data are presented as mean ±
SEM. For patient characteristics see Table 2.
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Page 6 of 13Figure 3 Hba and Hbb expression and localization in representative sections in control, COPD and IPF lungs (A, B, magnification
900×). Positive Hba and Hbb expression was seen mainly in the alveolar epithelium as well as in macrophages in the control and COPD lungs.
The alveolar epithelium (arrows) of patients with IPF displayed very weak staining in contrast to the situation in controls and patients with
COPD. Both Hb stainings were low or absent in the fibrotic areas and fibroblast foci. Morphometrical analyses (magnifications 300×), which were
conducted by excluding blood vessels and macrophages, show the sum of positive bronchiolar/alveolar epithelium and interstitium (Epi+Int) (C).
Hba and Hbb positive area in bronchiolar/alveolar epithelium only was evaluated separately by excluding blood vessels, macrophages and
interstitium (Epi) (D). Morphometrical analyses were evaluated from 6 control, 7 COPD and 7 IPF lung tissues. For detailed data see Additional
files 1 and 2 (Tables S1 and S2; as shown in the Tables two or three representative areas were analyzed from all stained sections). Data are
presented as mean ± SEM. For patient characteristics see Table 3.
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positivity, especially in the epithelial cells and inflamma-
tory cells but not in the interstitium or fibroblast foci in
IPF. In COPD, nitrotyrosine positivity was especially
localized in the epithelium and inflammatory cells (Fig-
ure 5). In addition, the control lung showed nitrotyro-
sine positivity with possible reasons including
anesthesia, ventilation with high oxygen and the gener-
ated stress reaction during lung surgery. Western blot
showed extensive nitrotyrosine positivity, but when nor-
malized against the loaded protein in the lane, no major
difference between these diseases could be seen (not
shown). However, if the total nitrotyrosine immunoreac-
tivity in the lung parenchyma of the inflated IPF and
COPD lung is calculated against the surface area, the
values in the COPD lung remain low which is then
related only to the large emphysematous areas in the
COPD lung with no tissue/alveoli. It remains unclear if
these kinds of differences can contribute to the oxidant
burden in the IPF or COPD lung in vivo.
Hb expression as tetramers in BALF and induced sputum
samples
The secretion of Hba and Hbb into BALF and induced
sputum supernatant was investigated in subjects with
normal lung function values to determine whether Hb
could be detected in these specimens. Furthermore, the
secreted forms were compared to those in the lung tis-
sue homogenates. The Hb forms differed between the
lung homogenates and BALF or sputum supernatants,
the major bands in the lung tissue consisting of the
Hba and Hbb complexes and monomers, while
the major band in the “secretions” corresponded to the
molecular weight of Hb tetramer (Figure 6). The bands
were similar in the BALF and sputum supernatants as
confirmed with the Hba and Hbß antibodies i.e there
was the presence of complexes containing both Hba
and Hbß i.e. tetramers in both secretions. Hb complexes
or monomers could barely be detected in the BALF or
sputum supernatants by Western analysis. It was not
possible to determine whether Hb levels vary between
Figure 4 Modification at cysteine 105 prevents formation of Hba complexes. (A) Schematic presentation of the spot-specific peptides,
obtained by MS, and the covered protein sequence. An asterisk indicates the cysteine-containing peptide 3024.6338. MS parameters represent
Aldente score, sequence coverage (SC) and the number of matched peptides (P). (B) MS spectrum representative for the Hba monomer. (C) Gel
parts corresponding to spots marked in Figure 1 revealed the presence of Hba complexes without (-A) and with (+A) alkylation prior to
separation. Homogenates of control lungs were separated by 2-DE (pH 6-11) and the total protein pattern visualized by silver staining.
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Page 8 of 13Figure 5 Nitrotyrosine expression and localization in representative sections of negative control, control, COPD and IPF lungs. Positive
nitrotyrosine expression is seen mainly in the epithelial cells and inflammatory cells in both diseases but not in the fibrotic lesions or fibroblast
foci in the IPF lung. There is some nitrotyrosine positivity also in the control (ex-smoker) lung. For patient characteristics see Table 3.
Figure 6 The expression of Hb by standard Western blot analysis in the lung homogenates (n = 6), BALF (n = 6) and induced sputum
supernatants (n = 7) of control subjects. BALF had been obtained from subjects with prolonged cough who had normal spirometry, BAL cell
profile and HRCT finding. Induced sputum was obtained from healthy non-smokers. The results indicate that the major Hb forms detectable by
the commercial antibodies differ between the lung tissue and BALF or sputum, the major band in the lung tissue being the Hba and Hbb (not
shown in this figure) complex, while it is detected as larger complexes corresponding to Hb tetramers in the “secretions”. The expression by
using the Hba and b antibodies in the BALF and sputum was very similar further suggesting that the band represents tetramer. Here only Hba
is shown. For patient characteristics see Table 4.
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ference i.e. the changes in the Hba complexes and also
Hb monomers in the tissues, were not clearly detectable
in the secretions.
Discussion
In the present study, unbiased proteomics and subse-
quent MS and Western blot analyses indicated reduced
levels of Hb (a, b) monomers and complexes in lung
specimens from patients with IPF compared to the con-
trols. According to the immunohistochemistry, normal
human lung expressed Hba and Hbb most prominently
in the alveolar epithelial cells while in the IPF lung, the
levels of both Hb monomers were very low or even
undetectable. Subsequent studies (2-DE, Western blot,
immunohistochemistry, morphometry) on COPD, a dis-
ease with a different type of parenchymal lung damage,
detected no or very minimal changes in the expression
of Hba and Hbb compared to control with both Hb
forms being localized mainly in the alveolar epithelium
of COPD lungs. A detailed MS-analysis indicated that a
disturbance in the complex formation of Hba in the IPF
lung was associated with the modification of a thiol
group (Cysa105) present in the Hba molecule. Addi-
tional studies on BALF samples and induced sputum
supernatants revealed that Hb could be detected in
these specimens mainly as tetramers.
There are several problems in proteomic studies
which are related to the sample type in various parench-
ymal lung diseases as reviewed in [34]. In the present
study, we examined lung tissue specimens in our pro-
teomic analyses from two different types of parenchymal
lung diseases i.e. IPF and COPD to obtain a broad per-
spective of the overall lung pathology. To avoid the pro-
blems and overlapping features of these diseases, IPF
cases were selected from never or ex-smokers with
short smoking histories, and COPD cases represented
end stage disease with severe emphysema. These find-
ings suggest that the changes in the Hb monomers and/
or complexes may be related to a specific type of par-
enchymal lung damage.
The human Hb molecules are a set of very closely
related proteins formed by symmetric pairing of a dimer
of polypeptide chains, the a- and b-globins, into a tetra-
meric structural and functional unit. The a2b2 molecule
represents the predominant adult Hb [35]. Originally
detected in erythroid cells, Hb expression has been
detected in eye, kidney, endometrium, activated macro-
phages and cultured alveolar epithelial cells [36-43]. Our
immunoblotting technique identified not only the Hba
and Hbb monomers but also their complexes in human
lungs, whereas decline in IPF was most significant in the
Hba complex. The positive immunoreactivity of the Hb
monomers in alveolar macrophages may be partly
related to red blood cell phagocytosis in the diseased
lung. In contrast, the expression of the Hb monomers in
the alveolar epithelial cells is in full agreement with pre-
vious findings on the airway epithelium [39].
The distributions of Hba and Hbb were evaluated in
human lung tissues by immunohistochemistry and their
expression by morphometry of areas which did not
include blood vessels or macrophages. Hba and Hbb
were mainly localized in alveolar cells. On the other
hand, the alveolar epithelium of patients with IPF dis-
played weaker staining in contrast to the controls, smo-
kers and patients with COPD. Interestingly, lung lavage
samples of smokers and COPD patients have been
shown to exhibit elevated concentrations of both iron
and ferritin compared to healthy non-smokers, suggest-
ing that cigarette smoke exposure can alter iron homeo-
stasis in the lung [44]. It is not known whether these
changes impact on the expression Hb in the COPD
lung, although some kind of association is not impossi-
ble. In agreement, immunohistochemistry of the COPD
lung revealed an intensively stained alveolar region con-
taining the Hb units. The situation is different in IPF
where the alveolar epithelium is replaced by a thick
fibrotic barrier against diffusion. Overall, these results
suggest that the two Hb monomers, Hba and Hbb may
play important, but different roles in the pathogenesis of
IPF and COPD.
The studies were extended to BALF and induced spu-
tum supernatants, since bronchofiberoscopy and BAL
are widely used in the differential diagnosis of IPF and
induced sputum reflects the airway inflammation/
pathology in chronic airway diseases. There is one study
that has evaluated Hb monomers from sputum by
SELDI-MS but this approach was focused on single pro-
teins, not protein complexes [45]. Our studies using
Western blot and commercial antibodies indicate that
Hb is secreted to these samples and is present mainly as
the larger complexes containing both Hba and Hbb cor-
responding to Hb tetramers. Since no complexes or
monomers could clearly be detected from these samples,
more sensitive and still unavailable methods will need to
be developed before this hypothesis can be tested. Inter-
estingly even concentrated BALF samples were negative
for Hba complexes, this representing a major difference
between the control and IPF lung by 2DE, Western blot
and morphometry in the lung tissue specimens. These
preliminary findings and their significance need to be
confirmed in future investigations.
The main function of Hb is to transport oxygen from
lung to tissues, and lung is very sensitive to changes in
oxygen delivery [35]. Hb represents a highly reactive
molecule which has, in addition to its oxygen-carrying
capacity, a multitude of enzymatic, protective, NO
neutralizing and ligand binding activities [46]. Protein
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part of the ubiquitous influence of NO on the cellular
signal transduction pathway [31,32], and the interactions
between NO and the Hb monomers have been shown
to regulate physiological responses such as vasodilata-
tion and vasoconstriction [47]. The detection of corre-
sponding alterations in Hba but not in Hbb complexes
by 2-DE in the present study might be explained by the
overlapping of Hbb complexes with other proteins
which allowed no reliable analysis. In fact, several inves-
tigators have emphasized the importance of Hbb nitro-
sylation/denitrosylation reactions in the pathologies of
many diseases in vivo [14]. Overall, this suggests that a
similar modification not only for Hba but also for Hbb
may occur simultaneously in the IPF lungs.
The levels of Hb complexes declined only in IPF for
reasons that remain unclear. The prevention of the
complex formation was investigated using both standard
and non-reducing Western blot, the results were similar.
It is possible that our reducing conditions did not cause
total reduction, especially of the highly abundant pro-
teins, in the specimens. One could also speculate that
the handling of the tissues may have caused some of the
changes, though all tissues underwent similar proces-
sing. This study included relatively low numbers of the
patients with IPF and COPD. Nonetheless, the results
were very clear, and the changes between the controls
and IPF were not only very significant but also could be
confirmed by many methods. In addition, this study is
the first to characterize the Hb in human lung and lung
diseases. The changes in the Hb composition could be
seen not only in the complex formation but also in both
Hb monomers. Instead, Hb was detected in the secre-
tions such as BALF and induced sputum mainly as high
molecular complexes corresponding to Hb tetramers.
Currently, no commercial ELISA is available for the
detection of different Hb variants in BALF or sputum to
allow the evaluations of their exact changes in various
clinical conditions. An understanding of the exact
mechanism and significance of the decline and modifica-
tion of Hb units in IPF but not in COPD will demand
further studies both in experimental models of lung
fibrosis and COPD.
Conclusions
T h i si st h ef i r s ts t u d ys h o w i n gt h ee x p r e s s i o no fH bi n
human lung and there mainly in alveolar epithelium.
In IPF, Hb complex formation is prevented. These
results can be considered to have widespread implica-
tions also in several other chronic inflammatory
diseases where oxygen transport/saturation and
exchange are disturbed.
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